Late 124I PET/CT Uptake Measurement—Assessment of Appropriate Examination Protocol in Benign Thyroid Diseases

Purpose This study aimed at investigating the performance of late 124I PET/CT for radioiodine uptake (RAIU) measurement at 336 hours after administration in patients with benign thyroid diseases requiring radioiodine therapy. Special attention was paid to the comparability of 124I uptake (124I-RAIU) to the clinical standard (131I-RAIU, probe measurement). Considering cost aspects, we sought to establish an economically reasonable examination protocol based on scan duration and administered activity. Methods List-mode PET data sets of 40-minute acquisition time were acquired 336 hours after administration of 1 MBq 124I in 18 patients. Different scan durations were simulated by different reconstruction intervals (RIs) ranging from 5 seconds to 40 minutes, and total thyroid activity was measured. Mean 124I-RAIU levels of each RI were compared with mean 131I-RAIU levels (3 MBq). A hypothetical scan duration or hypothetical activity, respectively, was sought by means of a proportion equation, considering that the length of an RI is equitable to a hypothetical activity. Results After 336 hours, the mean total thyroid activity was 254 ± 7.7 kBq for 131I and 26.9 ± 8.7 kBq for 124I. The mean 124I-RAIU and 131I-RAIU showed high levels of agreement for RI from 2 minutes to 40 minutes. Reconstruction interval shorter than 2 minutes did not result in sufficient agreement. Conclusions The present study confirmed the feasibility of late 124I PET/CT as alternative method for RAIU measurement in patients with benign thyroid diseases; 1 MBq 124I PET/CT scans as short as 2 minutes resulted in RAIU levels comparable to those of standard 131I-RAIU. The parameter “appropriate scan-duration activity product” is proposed to enable an economically reasonable examination protocol.

[1]  T. Winkens,et al.  Assessment of Minimum 124I Activity Required in Uptake Measurements Before Radioiodine Therapy for Benign Thyroid Diseases , 2016, The Journal of Nuclear Medicine.

[2]  Paolo Vitti,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ASSOCIAZIONE MEDICI ENDOCRINOLOGI MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND MANAGEMENT OF THYROID NODULES--2016 UPDATE. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[3]  R. Carson,et al.  Evaluation of bias and variance in low-count OSEM list mode reconstruction , 2015, Physics in medicine and biology.

[4]  T Carlier,et al.  Clinical NECR in 18F-FDG PET scans: optimization of injected activity and variable acquisition time. Relationship with SNR , 2014, Physics in medicine and biology.

[5]  T. Winkens,et al.  Multimodal evaluation of 2-D and 3-D ultrasound, computed tomography and magnetic resonance imaging in measurements of the thyroid volume using universally applicable cross-sectional imaging software: a phantom study. , 2014, Ultrasound in medicine & biology.

[6]  S. Schoenberg,et al.  Dependence of image quality on acquisition time for the PET/CT Biograph mCT. , 2014, Zeitschrift fur medizinische Physik.

[7]  T. Winkens,et al.  Low-activity (124)I-PET/low-dose CT versus (131)I probe measurements in pretherapy assessment of radioiodine uptake in benign thyroid diseases. , 2014, The Journal of clinical endocrinology and metabolism.

[8]  D. Driesch,et al.  Low-Activity 124I-PET/Low-Dose CT Versus 99mTc-Pertechnetate Planar Scintigraphy or 99mTc-Pertechnetate Single-Photon Emission Computed Tomography of the Thyroid: A Pilot Comparison , 2013, Clinical Nuclear Medicine.

[9]  Martin Freesmeyer,et al.  Differential diagnosis of thyroid nodules via real-time PET/ultrasound (US) fusion in a case of co-existing medullary thyroid cancer and adenoma. , 2013, The Journal of clinical endocrinology and metabolism.

[10]  Markus Luster,et al.  EANM Dosimetry Committee Series on Standard Operational Procedures for Pre-Therapeutic Dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  J. Anthony Parker,et al.  The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0* , 2012, The Journal of Nuclear Medicine.

[12]  Marla B. K. Sammer,et al.  Evaluation of Optimal Acquisition Duration or Injected Activity for Pediatric 18F-FDG PET/CT , 2011, The Journal of Nuclear Medicine.

[13]  H. Gharib,et al.  Thyroid nodule guidelines: agreement, disagreement and need for future research , 2011, Nature Reviews Endocrinology.

[14]  A. Bockisch,et al.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  Martin A. Lodge,et al.  124I PET-Based 3D-RD Dosimetry for a Pediatric Thyroid Cancer Patient: Real-Time Treatment Planning and Methodologic Comparison , 2009, Journal of Nuclear Medicine.

[16]  Julian C. Matthews,et al.  Bias in iterative reconstruction of low-statistics PET data: benefits of a resolution model , 2009, 2009 IEEE Nuclear Science Symposium Conference Record (NSS/MIC).

[17]  Chisato Kondo,et al.  Comparison of Imaging Protocols for 18F-FDG PET/CT in Overweight Patients: Optimizing Scan Duration Versus Administered Dose , 2009, Journal of Nuclear Medicine.

[18]  A. Bockisch,et al.  Optimized 124I PET Dosimetry Protocol for Radioiodine Therapy of Differentiated Thyroid Cancer , 2008, Journal of Nuclear Medicine.

[19]  B. Wolffenbuttel,et al.  The diagnostic value of 124I-PET in patients with differentiated thyroid cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  S. Larson,et al.  Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  C. Reiners,et al.  Procedure guideline for radioiodine test (version 2) , 2003, Nuklearmedizin.

[22]  J. Franklyn,et al.  Evaluation of Thyroid Function in Health and Disease , 2000 .

[23]  D. Price,et al.  Procedure guideline for thyroid uptake measurement: 1.0. Society of Nuclear Medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  D. Price,et al.  Procedure Guideline for Thyroid Uptake: 1.0 , 1996 .

[25]  L. Hegedüs,et al.  Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. , 1988, BMJ.

[26]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[27]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[28]  Konstantin Nikolaou,et al.  Towards tracer dose reduction in PET studies: Simulation of dose reduction by retrospective randomized undersampling of list-mode data. , 2016, Hellenic journal of nuclear medicine.

[29]  M. Freesmeyer,et al.  Time efficient 124I-PET volumetry in benign thyroid disorders by automatic isocontour procedures: mathematic adjustment using manual contoured measurements in low-dose CT , 2014, Annals of Nuclear Medicine.